The cutoff point >25 % of tumor cells expressing CD163 in tumor samples is correlated to DSS and DRFS rates suggesting that CD163 might be useful as macrophage/cancer cell fusion marker in clinical context. This evidence concerns the gene CD163 and neoplasm.